CD38 and Miyoshi myopathy: It has also been shown that mezigdomide increases CD38 cell surface expression in MM cell lines, leading to enhanced antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) with subsequent daratumumab exposure [63].